Julie ONeill - Alexion Pharmaceuticals Executive Vice President - Global Operations
President
Ms. Julie ONeill is Executive Vice President Global Operations of the Alexion Pharmaceuticals, Inc. She was with Alexion since February 2014 and has served as Executive Vice President of Global Operations since January 2015. From January 2014 to January 2015, Ms. ONeill was Senior Vice President Global Manufacturing Operations and General Manager of Alexion Pharma International Trading. Prior to joining Alexion, Ms. ONeill served in various leadership positions at Gilead Sciences from February 1997 to February 2014 including Vice President of Operations and General Manager of Ireland from 2011 to 2014. Prior to Gilead Sciences, Ms. ONeill held leadership positions at Burnil Pharmacies and Helsinn Birex Pharmaceuticals. She is the Chairperson for the National Standards Authority of Ireland and is a member of the Boards of the National Institute for Bioprocessing Research Training and the American Chamber of Commerce, Ireland since 2015.
| Age | 50 |
| Tenure | 9 years |
| Phone | 475 230-2596 |
| Web | www.alexion.com |
Alexion Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 10.08 % which means that it generated a profit of $10.08 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on stockholder's equity (ROE) of 4.43 %, meaning that it created $4.43 on every $100 dollars invested by stockholders. Alexion Pharmaceuticals' management efficiency ratios could be used to measure how well Alexion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.88 B in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Alexion Pharmaceuticals has a current ratio of 4.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Alexion Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Alexion Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alexion Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alexion to invest in growth at high rates of return. When we think about Alexion Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| David Schneider | ServiceNow | 51 | |
| Gregory Miller | Genuine Parts Co | N/A | |
| William II | Genuine Parts Co | 46 | |
| Masatoshi Suzuki | ServiceNow | N/A | |
| James Neill | Genuine Parts Co | 62 | |
| Joshua Dicker | Getty Realty | 60 | |
| Derek Goshay | Genuine Parts Co | N/A | |
| Cathy Mauzaize | ServiceNow | N/A | |
| Heather Kaminetsky | MYT Netherlands Parent | N/A | |
| Carol Yancey | Genuine Parts Co | 57 | |
| Scott Sonnemaker | Genuine Parts Co | 55 | |
| Mark Olear | Getty Realty | 60 | |
| Detlef Krause | ServiceNow | N/A | |
| Brian Dickman | Getty Realty | 48 | |
| Napoleon Rutledge | Genuine Parts Co | 47 | |
| Paul Donahue | Genuine Parts Co | 67 | |
| Danion Fielding | Getty Realty | 47 | |
| Michal Tsur | Kaltura | 50 | |
| Lee Maher | Genuine Parts Co | 68 | |
| Herbert Nappier | Genuine Parts Co | 49 | |
Management Performance
| Return On Equity | 4.43 | |||
| Return On Asset | 10.08 |
Alexion Pharmaceuticals Leadership Team
Elected by the shareholders, the Alexion Pharmaceuticals' board of directors comprises two types of representatives: Alexion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alexion. The board's role is to monitor Alexion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Alexion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alexion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Miller, Senior Vice President Global Chief Compliance Officer | ||
| David Anderson, CFO | ||
| Felix Baker, Director | ||
| Dominique Monnet, Senior Vice President Chief Marketing Officer | ||
| Saqib Islam, Senior Vice President Chief Strategy and Portfolio Officer | ||
| John Orloff, Executive Vice President Head of Research and Development | ||
| Ludwig Hantson, CEO, Director | ||
| Vikas Sinha, CFO, Executive Vice President | ||
| Andreas Rummelt, Independent Director | ||
| Julie ONeill, Executive Vice President - Global Operations | ||
| Brian Goff, Chief Commercial Officer | ||
| Clare Carmichael, Chief Human Resource Officer, Senior Vice President | ||
| Deborah Dunsire, Independent Director | ||
| Ellen Chiniara, Executive Vice President General Counsel, Corporate Secretary | ||
| Leonard Bell, CEO, Treasurer, Director | ||
| Paul Friedman, Director | ||
| Christopher Coughlin, Independent Director | ||
| Martin Mackay, Global Head of RandD and Executive VP | ||
| Heidi Wagner, Senior Vice President - Global Governmental Affairs | ||
| Ann Veneman, Independent Director | ||
| Paul Clancy, CFO | ||
| AnneMarie Law, Chief Patient and Employee Experience Officer, Executive Vice President | ||
| Francois Nader, Director | ||
| Judith Reinsdorf, Director | ||
| Indrani Franchini, Executive Vice President Chief Compliance Officer | ||
| John Moriarty, Senior Vice President General Counsel | ||
| Alvin Parven, Independent Director | ||
| Michele Burns, Independent Director | ||
| David Hallal, CEO and Director | ||
| Douglas Norby, Lead Independent Director | ||
| David Brennan, Independent Director | ||
| Carsten Thiel, Senior Vice President EMEA and Asia Pacific | ||
| John Mollen, Director |
Alexion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alexion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 4.43 | |||
| Return On Asset | 10.08 | |||
| Profit Margin | 10.89 % | |||
| Operating Margin | 52.12 % | |||
| Current Valuation | 39.17 B | |||
| Shares Outstanding | 221.02 M | |||
| Shares Owned By Insiders | 0.34 % | |||
| Shares Owned By Institutions | 88.27 % | |||
| Number Of Shares Shorted | 8.46 M | |||
| Price To Earning | 58.24 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alexion Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alexion Pharmaceuticals' short interest history, or implied volatility extrapolated from Alexion Pharmaceuticals options trading.
Pair Trading with Alexion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alexion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alexion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to CenterPoint Energy could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CenterPoint Energy when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CenterPoint Energy - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CenterPoint Energy to buy it.
The correlation of CenterPoint Energy is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CenterPoint Energy moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CenterPoint Energy moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CenterPoint Energy can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Alexion Stock
If you are still planning to invest in Alexion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alexion Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |